

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listings of claims in the application

1-33. (canceled)

34. (previously presented) A composition comprising a CD20 binding molecule, wherein the CD20 binding molecule comprises a light chain variable region and a heavy chain variable region, wherein:

the light chain variable region comprises:

a CDRL1 amino acid sequence of SEQ ID NO:5;

a CDRL2 amino acid sequence of SEQ ID NO:13;

a CDRL3 amino acid sequence SEQ ID NO:19, and

the heavy chain variable region comprises:

a CDRH1 amino acid sequence of SEQ ID NO:25;

a CDRH2 amino acid sequence of SEQ ID NO:39; and

a CDRH3 amino acid sequence of SEQ ID NO:57

35-39. (canceled)

40. (withdrawn) A method of treating B cell lymphoma comprising administering to a subject a composition comprising a CD20 binding molecule, wherein the CD20 binding molecule comprises a light chain variable region and a heavy chain variable region, wherein:

the light chain variable region comprises:

a CDRL1 amino acid sequence of SEQ ID NO:5;

a CDRL2 amino acid sequence of SEQ ID NO:13; and

a CDRL3 amino acid sequence of SEQ ID NO:19, and

the heavy chain variable region comprises:

a CDRH1 amino acid sequence of SEQ ID NO:25;

a CDRH2 amino acid sequence of SEQ ID NO:39; and

a CDRH3 amino acid sequence of SEQ ID NO:57.

41. (withdrawn) The method of Claim 40, wherein the CD20 binding molecule comprises the AME 33 Fab.
42. (withdrawn) The method of Claim 40, wherein the CD20 binding molecule has a binding affinity ( $K_d$ ) for human CD20 of  $5.0 \times 10^{-10}$  M or less, and a dissociation rate ( $k_{off}$ ) for human CD20 of  $5.0 \times 10^{-4} \text{ s}^{-1}$  or less.
43. (withdrawn) The method of Claim 42, wherein the CD20 binding molecule has a binding affinity ( $K_d$ ) for human CD20 of  $1.5 \times 10^{-10}$  M or less.
44. (withdrawn) The method of Claim 42, wherein the CD20 binding molecule has a dissociation rate ( $k_{off}$ ) for human CD20 of  $2.5 \times 10^{-4} \text{ s}^{-1}$  or less.
45. (withdrawn) The method of Claim 42, wherein the CD20 binding molecule has an association rate ( $k_{on}$ ) for human CD20 of  $5.0 \times 10^{-5} \text{ M}^{-1} \text{ s}^{-1}$  or greater.
46. (withdrawn) The method of Claim 40, wherein the B cell lymphoma is Non-Hodgkin's lymphoma.
47. (withdrawn) The method of Claim 46, wherein the Non-Hodgkin's lymphoma is Waldenstrom's macroglobulinemia.
48. (previously presented) The composition of Claim 34, wherein the light chain variable region comprises an amino acid sequence of SEQ ID NO:59 and the heavy chain variable region comprises an amino acid sequence of SEQ ID NO:61.
- 49-50. (canceled)
51. (previously presented) A composition comprising a CD20 binding molecule, wherein the CD20 binding molecule comprises a light chain amino acid sequence of SEQ ID NO:67 and a heavy chain amino acid sequence of SEQ ID NO:69.